Utilisateur:Karina79/Brouillon

Cette page est un brouillon appartenant à Karina79

Conseils de rédaction

→ N'hésitez pas à publier sur le brouillon un texte inachevé et à le modifier autant que vous le souhaitez.
→ Pour enregistrer vos modifications au brouillon, il est nécessaire de cliquer sur le bouton bleu : « Publier les modifications ». Il n'y a pas d'enregistrement automatique.

Si votre but est de publier un nouvel article, votre brouillon doit respecter les points suivants :

Respectez le droit d'auteur en créant un texte spécialement pour Wikipédia en français (pas de copier-coller venu d'ailleurs).
Indiquez les éléments démontrant la notoriété du sujet (aide).
Liez chaque fait présenté à une source de qualité (quelles sources – comment les insérer).
Utilisez un ton neutre, qui ne soit ni orienté ni publicitaire (aide).
Veillez également à structurer votre article, de manière à ce qu'il soit conforme aux autres pages de l'encyclopédie (structurer – mettre en page).

→ Si ces points sont respectés, pour transformer votre brouillon en article, utilisez le bouton « publier le brouillon » en haut à droite. Votre brouillon sera alors transféré dans l'espace encyclopédique.

==HRA Pharma==

HRA Pharma is a global independent pharmaceutical company dedicated to niche areas of women’s health^[1] and endocrinology^[2]. Headquartered in Paris, France HRA Pharma has direct local operations in 9 European countries (Belgium, France, Germany, Ireland, Italy, Portugal, Spain, Switzerland, the United Kingdom) and a broad network of distribution partners worldwide. The company’s products are registered and sold in more than 80 countries worldwide. HRA Pharma employs 130 people globally (as of Sept 2014). In 2013, the company’s revenue was €60 million.^[3]

Fichier:Hrapharma.jpg

HRA Pharma Headquarters in Paris, France

===History=== HRA Pharma began in 1996 as a development project by André Ulmann, physician and former Medical Director and Head of Clinical Research for Roussel-Uclaf and Hoechst-Marion-Roussel. André Ulmann identified women’s reproductive health as an important and poorly addressed field and focused on emergency contraception^[4], an area with a significant unmet medical need. ^[5] HRA Pharma was incorporated as a privately held company in 1998. Its mission statement from the outset was to “develop and market medicines that respond to a clear-cut medical need but do not trigger interest from large pharmaceutical companies”.During the first few years of business, Dr. Ulmann built up a small team of professionals in Paris that pioneered HRA Pharma’s first product, NorLevo (levonorgestrel^[6]) – an emergency contraceptive pill. Launched in France in 1999^[7], it was approved for marketing throughout Europe one year later^[8]^[9]^[10]^[11]. Given the interest generated by this product from a public health perspective, the French authorities enacted policies to make it widely accessible to patients^[12]. As a result, it became the first hormonal contraceptive product to be made available without prescription^[13], and the first to be made available free of charge to under 18 year olds^[14]. NorLevo® is now available in over 50 countries worldwide^[15]. The success of Norlevo enabled the company to expand its women’s health franchise, and led to the development of another compound - ulipristal acetate^[16], a proprietary first-in-class selective progesterone receptor modulator. Following a complete development program, ulipristal acetate was approved for use as emergency contraception in 2009^[17] and is currently marketed under the trade name ellaOne or ella (30 mg tablet) in over 60 countries. Ulipristal acetate is also available in a different strength and different dosage regimen as Esmya®, a treatment for uterine fibroids^[18]. In 2014, the company launched Clareva, a symptomatic treatment of genital herpes^[19]. In parallel to the development of its women’s health franchise, the company expanded into the field of rare endocrine diseases and diversified its portfolio through organic growth, partnerships and acquisitions. In the field of rare endocrine diseases, the company’s markets treatments for rare, severe diseases including Cushing’s syndrome^[20] and adrenal cortical cancer^[21]. HRA Pharma endocrine brands include Ketoconazole HRA (ketoconazole^[22]), Lysodren (mitotane^[23]) and Metopirone (metyrapone^[24]). The company is a specialist in niche areas of women’s health and endocrinology.

===Key products===

Women’s health • Clareva (oxidised triglycerides) • ellaOne (ulipristal acetate^[25]) • esmya (ulipristal acetate^[26]) • NorLevo (levonorgestrel^[27])

Endocrinology • Ketoconazole HRA (ketoconazole^[28]) • Lysodren (mitotane^[29]) • Metopirone (metyrapone^[30])

===Corporate governance=== Erin Gainer has been HRA Pharma's Chief Executive Officer since 2009. André Ulmann is the Founder of HRA Pharma and Chairman of its Board of Directors, a position he has held since 2009^[31].

Vous êtes ici sur la page personnelle d’un utilisateur de Wikipédia en français.
Cette page ne fait pas partie de l’espace encyclopédique de Wikipédia.

Si vous avez accédé à cette page depuis un autre site que celui de Wikipédia en français, c’est que vous êtes sur un site miroir ou un site qui fait de la réutilisation de contenu. Cette page n’est peut-être pas à jour et l’utilisateur identifié n’a probablement aucune affiliation avec le site sur lequel vous vous trouvez. L’original de cette page se trouve à l'adresse suivante : https://fr.wikipedia.org/wiki/Utilisateur:Karina79/Brouillon.

[1] ttps://en.wikipedia.org/wiki/Women%27s_health

[2] ttps://en.wikipedia.org/wiki/Endocrinology

[3] www.hra-pharma.com

[4] ttps://en.wikipedia.org/wiki/Emergency_contraception

[5] "Créer une entreprise pharmaceutique sans capital" http://ecole.org/fr/seances/SEM127

[6] ttps://en.wikipedia.org/wiki/Levonorgestrel

[7] ttp://agence-prd.ansm.sante.fr/php/ecodex/extrait.php?specid=68196192)

[8] ttp://www.legemiddelverket.no/Legemiddelsoek/Sider/default.aspx?searchquery=levonorgestrel&f=Han;MtI;Vir;ATC;Var;Mar;Mid;Avr;&pane=0

[9] ttp://www.cbg-meb.nl/CBG/en/human-medicines/geneesmiddeleninformatiebank/default.htm

[10] ttp://www.fimea.fi/medicines/fimeaweb

[11] ttp://www.fagg-afmps.be/fr/items/banque_donnees/

[12] Improving access : “the French Experience” https://www.guttmacher.org/pubs/tgr/05/5/gr050510.html)

[13] ttp://www.assemblee-nationale.fr/legislatures/11/pdf/rap-info/i2593.pdf

[14] ttp://www.legifrance.gouv.fr/affichTexte.do;jsessionid=F91A2E848D9F21C78D134C3879B70A56.tpdjo02v_3?cidTexte=LEGITEXT000005632081&dateTexte=20141120

[15] Worldwide availability: http://www.hra-pharma.com/index.php/en/our_products/womens_health/emergency_contraception/norlevo)

[16] ttps://en.wikipedia.org/wiki/Ulipristal_acetate

[17] ttp://www.ema.europa.eu/ema/index.jsp?curl=pages/medicines/human/medicines/001027/human_med_000758.jsp&mid=WC0b01ac058001d124)

[18] ttps://en.wikipedia.org/wiki/Uterine_fibroids

[19] ttps://en.wikipedia.org/wiki/Genital_herpes

[20] ttps://en.wikipedia.org/wiki/Cushing_syndrome

[21] ttps://en.wikipedia.org/wiki/Adenocortical_carcinoma

[22] ttps://en.wikipedia.org/wiki/Ketoconazole

[23] ttps://en.wikipedia.org/wiki/Mitotane

[24] ttps://en.wikipedia.org/wiki/Metyrapone

[25] ttps://en.wikipedia.org/wiki/Ulipristal_acetate

[26] ttps://en.wikipedia.org/wiki/Ulipristal_acetate

[27] ttps://en.wikipedia.org/wiki/Levonorgestrel

[28] ttps://en.wikipedia.org/wiki/Ketoconazole

[29] ttps://en.wikipedia.org/wiki/Mitotane

[30] ttps://en.wikipedia.org/wiki/Metyrapone

[31] ttp://www.hra-pharma.com/index.php/fr/notre_entreprise/decouvrir_hra_pharma/notre_gouvernance

[1]

[2]

[3]

[4]

[5]

[6]

[7]

[8]

[9]

[10]

[11]

[12]

[13]

[14]

[15]

[16]

[17]

[18]

[19]

[20]

[21]

[22]

[23]

[24]

[25]

[26]

[27]

[28]

[29]

[30]

[31]